ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

AIM AIM ImmunoTech Inc

0.415
-0.0101 (-2.38%)
Jun 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 229,498
Bid Price
Ask Price
News -
Day High 0.4267

Low
0.3054

52 Week Range

High
0.7487

Day Low 0.391
Share Name Share Symbol Market Stock Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0101 -2.38% 0.415 18:29:38
Open Price Low Price High Price Close Price Previous Close
0.4267 0.391 0.4267 0.3973 0.4251
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
442 229,498 US$ 0.4178366 US$ 95,893 - 0.3054 - 0.7487
Last Trade Type Quantity Price Currency
18:52:08 2 US$ 0.4124 USD

AIM ImmunoTech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
87.92M 48.84M - 202k -28.96M -0.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AIM ImmunoTech News

Date Time Source News Article
6/10/202407:55GlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Pitch..
6/03/202409:15Edgar (US Regulatory)Form 8-K - Current report
6/03/202409:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
6/03/202408:15GlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch..
5/31/202407:30GlobeNewswire Inc.AIM ImmunoTech Announces Pricing of $2.0 Million Registered..
5/31/202407:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
5/20/202408:15GlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor..
5/16/202406:30GlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results..
5/15/202415:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/09/202407:50GlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial..
5/07/202407:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/07/202407:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AIM Message Board. Create One! See More Posts on AIM Message Board See More Message Board Posts

Historical AIM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.390.45890.360.4113203317,1780.0256.41%
1 Month0.410.4690.30540.4110227399,7030.0051.22%
3 Months0.440.620.30540.4462117300,021-0.025-5.68%
6 Months0.4620.620.30540.4346511228,806-0.047-10.17%
1 Year0.500.74870.30540.4778005180,886-0.085-17.00%
3 Years2.152.220.2911.02241,480-1.74-80.70%
5 Years1.968.750.2912.511,415,490-1.55-78.83%

AIM ImmunoTech Description

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Your Recent History

Delayed Upgrade Clock